Effects of Stellate Ganglion Block on Delirium and Circadian Rhythm in Geriatric Intensive Care Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-99
SponsorAntalya Training and Research Hospital

About this trial

Delirium is a common complication in elderly intensive care unit (ICU) patients and is associated with poor clinical outcomes. Circadian rhythm disruption is considered an important contributing factor in delirium development. Stellate ganglion block (SGB) may modulate autonomic nervous system activity and improve circadian rhythm regulation.

This prospective randomized placebo-controlled trial aims to evaluate the effects of ultrasound-guided stellate ganglion block on delirium incidence and circadian rhythm in ICU patients aged 65 years and older. Delirium will be assessed using validated clinical scales, and circadian rhythm will be evaluated through serial measurements of serum melatonin and plasma cortisol levels

Eligibility criteria

Qualifiers

Patients aged 65 years or older expected to remain in the intensive care unit for more than 48 hours

RASS score > -4

Disqualifiers

History of neurodegenerative disease (e.g., Alzheimer's disease, dementia, vascular dementia)

Uncontrolled psychiatric disorders

Alcohol use disorder and/or substance abuse

History of traumatic brain injury or ischemic/hemorrhagic cerebrovascular event

Trial design

Treatments tested in this trial

  • stellate ganglion block with 0.5% bupivacaine
  • Placebo Injection

Treatment groups

130 Participants
are divided into 2 treatment groups